ASE · Drug Manufacturers - Specialty & Generic

Apimeds Pharmaceuticals US, Inc. (APUS) Stock

$4.69 -14.88% ASE: APUS Healthcare

Valuation

MetricValue
Price$4.69
Market Cap$7.08M
P/E Ratio-0.09
P/B Ratio0.07
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$59.70
52-Week Low$1.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-58.98%
ROA-45.58%
ROCE-18.05%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.14
Current Ratio1.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-1.0M$-1.0M$-12.0M
Net Profit$-1.0M$-1.0M$-1.0M$-1.0M$-6.0M
EPS$-8.08$-5.27$-6.13$-11.00$-5.50
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$0$0$164.0M
Total Liabilities$0$1.0M$0$1.0M$11.0M
Cash$0$0$0$0$2.0M
Borrowings$0$1.0M$0$1.0M$8.0M

Latest News

Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon NYSE · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$0$-1.0M$-1.0M$-9.0M
Investing Cash Flow$0$0$0$0$-10.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$0$0$0$10.0M
Free Cash Flow$-1.0M$0$-1.0M$-1.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.39
FCF Yield-200.92%
Quick Ratio0.51
Interest Coverage-4.47
Return 1Y-96.00%
Return 3Y—
Return 5Y—

Ownership

Insiders Held58.71%
Institutions Held2.97%
Institutions Float Held7.20%
Institutional HolderSharesReport Date
Hemenway Trust Company LLC274,0002026-03-31
Vanguard Capital Management LLC95,9292026-03-31
Geode Capital Management, LLC40,0512026-03-31
Vanguard Fiduciary Trust Co24,0392026-03-31
Two Sigma Securities, LLC10,5502026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTXAN2 Therapeutics, Inc. $4.40 -5.98% -5.24 $158.47M 0.00%
IGCIGC Pharma, Inc. $0.28 -1.75% -3.34 $28.02M 0.00%
MIRAMIRA Pharmaceuticals, Inc. $0.75 +6.05% -0.53 $31.33M 0.00%
MLSSMilestone Scientific, Inc. $0.35 -2.78% -7.97 $30.96M 0.00%
MYOMyomo Inc. $1.43 +1.42% -5.02 $55.25M 0.00%

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. is led by CEO Vinod Menon, employs 2 people, headquartered in US, publicly traded since 2025.

Apimeds Pharmaceuticals US, Inc. (APUS) stock trades at $4.69 with a market capitalization of $7.08M. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of 0.07, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.51 and $59.70, and currently trades 92.1% below its 52-week high.

On profitability, Apimeds Pharmaceuticals US, Inc. generates a return on equity (ROE) of -58.98%, return on capital employed of -18.05%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides